TellBio, Inc.

TellBio, Inc is a development stage biotechnology company based in Beverly, Massachusetts, with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutic platform, TellDx and TellRx, respectively. The foundation of the Company’s approach – detection of and targeting CTCs – is exclusively licensed from Massachusetts General Hospital and is based on decades of academic and clinical research. TellBio’s vision is to free patients and their families from the tyranny of cancer via both its TellDx and TellRx platforms. TellDx is a fully functional diagnostic solution aimed at detecting live CTCs from patient liquid biopsies. TellRx is the therapeutics platform that generates novel anti-cancer medicines by specifically targeting CTCs. The synergy of these platforms offers TellBio a unique opportunity to detect CTCs via a first-in-class, best-in-class microfluidic diagnostic platform and target CTCs with novel therapeutics to improve outcomes of patients with cancer.